Table 2.
Referrals, visits, and germline testing results*
| C1 (n = 281) | C2 (n = 493) | C3 (n = 133) | Total (n = 907) | ||
|---|---|---|---|---|---|
| Variables | No. (%) | No. (%) | No. (%) | No. (%) | P trend † |
| GC visits (% of tNGS) | 41 (14.6) | 97 (19.7) | 44 (33.1) | 182 (20.1) | <.001 |
| Due to MTB recommendations or workflow | 3 (1.1) | 34 (6.9) | 18 (13.5) | 55 (6.1) | <.001 |
| Independent of MTB | 38 (13.5) | 63 (12.8) | 26 (19.5) | 127 (14.0) | .23 |
| Germline testing (% of tNGS) | 31 (11.0) | 69 (14.0) | 38 (28.6) | 138 (15.2) | <.001 |
| Due to MTB recommendations or workflow | 2 (0.7) | 16 (3.2) | 15 (11.3) | 33 (3.6) | <.001 |
| Independent of MTB | 29 (10.3) | 53 (10.8) | 23 (17.3) | 105 (11.6) | .09 |
| (+) GL findings (% of tNGS) | 4 (1.4) | 10 (2.0) | 10 (7.5) | 24 (2.6) | .003 |
| Due to MTB recommendations or workflow | 1 (0.4) | 2 (0.4) | 3 (2.3) | 6 (0.7) | .12 |
| Independent of MTB | 3 (1.1) | 8 (1.6) | 7 (5.3) | 18 (2.0) | .02 |
*
Patients whose tNGS reports were presented at MTB before (C1) and after (C2) the addition of review of tNGS for potential germline alterations by clinical genetics at MTB and after (C3) the implementation of a formal integrated cancer genetics approach to coordinate post-MTB GC and integrate patients’ genetics appointments within their existing cancer appointments. GC = genetic counseling; MTB = Molecular Tumor Board; tNGS = tumor-only next-generation sequencing.
†
All P values calculated by Extended Mantel-Haenszel χ2 for linear trend.